BioCentury | Jul 3, 2020
Management Tracks

Angus Grant joins BeiGene; plus changes at Sarepta, RegenxBio, BioMarin, Novavax, Whitehead, Akcea and more

...EVP, legal and compliance, effective Sept. 1. Joannes is group general counsel of Roquette Frères. PDC*line...
...Inc. Oncopeptides AB Codiak BioSciences Inc. ImmVira Co. Ltd. Kyowa Kirin Co. Ltd. Inovio Pharmaceuticals Inc. Mereo BioPharma Group plc Leo Pharma A/S PDC*line...
BioCentury | Jun 23, 2020
Deals

Vaccines deal with Sanofi to propel Translate Bio’s mRNA therapeutics platform

...resources to explore its lung delivery platform in additional pulmonary diseases, including primary ciliary dyskinesia (PDC...
BioCentury | Jan 23, 2020
Financial News

Jan. 22 Financial Quick Takes: Genmab-J&J, Adaptimmune, Revolution, PDC*line

...in Phase I/II testing for solid tumors (see “Revolution Raises $100M” ). PDC*line raises €20M PDC*line...
...Belgium. PDC*line is developing allogeneic cancer cell therapies based on plasmacytoid dendritic cells; lead therapy PDC*lung01...
...RAFT1) - Mammalian target of rapamycin Hongjiang Li, Staff Writer Revolution Medicines Inc. Genmab A/S Johnson & Johnson Adaptimmune Therapeutics plc PDC*line...
BioCentury | Feb 26, 2019
Company News

CytomX R&D day reveals Probody toxicity, chopped BMS deal

...Programmed cell death 1; PD-L1 (B7-H1; CD274) - Programmed cell death 1 ligand 1 Chris Lieu CD166 PDC...
BioCentury | Jan 26, 2019
Product Development

Target wide, test narrow in lupus

...IFNα-Kinoid is a vaccine against IFNα, which is primarily produced by plasmacytoid dendritic cells ( PDC...
BioCentury | Mar 9, 2018
Company News

Pfizer ends PDC deal with CytomX

...announced plans to report next half data from the Phase I/II PROCLAIM-CX-2009 trial of CD166 PDC...
...Inc. (NASDAQ:CTMX), South San Francisco, Calif. Pfizer Inc. (NYSE:PFE), New York, N.Y. Business: Cancer Jennie Walters CD166 PDC...
BioCentury | Oct 13, 2017
Company News

Cellectar and Pierre Fabre extend PDC deal

...and Pierre Fabre Group (Castres, France) extended a 2015 deal to develop phospholipid drug conjugates (PDC...
BioCentury | Jul 3, 2017
Clinical News

CytomX begins Phase I/II of CX-2009 in solid tumors

...CytomX Therapeutics Inc. (NASDAQ:CTMX) began the open-label, U.S. Phase I/II PROCLAIM-CX-2009 trial to evaluate CD166 PDC...
...evaluate dose-limiting toxicities (DLTs). Its secondary endpoints are objective response rate (ORR) and pharmacokinetics. CD166 PDC...
...protein antigen coupled to DM4. CytomX Therapeutics Inc. (NASDAQ:CTMX), South San Francisco, Calif. Product: CD166 PDC...
BioCentury | Dec 9, 2016
Financial News

PDC*line completes venture financing

...million) in capital and €1.4 million ($1.5 million) in debt. PDC*line Pharma , Grenoble, France Alicia Parker PDC*line...
BioCentury | Nov 12, 2015
Product R&D

Probodies, anticancer

...non-small cell lung cancer (NSCLC) or ovarian cancer xenografts, a CD166 probody-drug conjugate ( CD166 PDC...
...nomination of a clinical candidate. The company plans to begin clinical testing of an CD166 PDC...
Items per page:
1 - 10 of 25